Cyclophosphamide treatment of steroid dependent nephrotic syndrome

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

Cyclophosphamide and the related nitrogen mustard –derived alkylating agent ifosfamide were developed by Norbert Brock and ASTA (now Baxter Oncology). Brock and his team synthesised and screened more than 1,000 candidate oxazaphosphorine compounds. [47] They converted the base nitrogen mustard into a nontoxic "transport form". This transport form was a prodrug, subsequently actively transported into cancer cells. Once in the cells, the prodrug was enzymatically converted into the active, toxic form. The first clinical trials were published at the end of the 1950s. [48] [49] [50] In 1959 it became the eighth cytotoxic anticancer agent to be approved by the FDA . [20]

Cyclophosphamide treatment of steroid dependent nephrotic syndrome

cyclophosphamide treatment of steroid dependent nephrotic syndrome

Media:

cyclophosphamide treatment of steroid dependent nephrotic syndromecyclophosphamide treatment of steroid dependent nephrotic syndromecyclophosphamide treatment of steroid dependent nephrotic syndromecyclophosphamide treatment of steroid dependent nephrotic syndromecyclophosphamide treatment of steroid dependent nephrotic syndrome

http://buy-steroids.org